# US 2012/0269812 A1 · Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269812 A1
- Document ID: US20120269812A1
- Status: Published application
- Kind: A1
- Application number: 13/451,135
- Filed: 2012-04-19
- Published: 2012-10-25
- Earliest claimed: 2011-04-19
- Assignees: Merrimack Pharmaceuticals, Inc.
- Inventors: Jason BAUM; Bryan JOHNSON; Alexey Alexandrovich LUGOVSKOY; Lihui XU; Neeraj KOHLI; Jonathan Basil FITZGERALD; Sharlene ADAMS
- Web page: https://patentgrep.com/patent/US20120269812A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 35/00: Antineoplastic agents
- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C07K 16/40: against enzymes
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

## Claims

### Claim at position 1

-194. (canceled)

### Claim 195

Polyvalent bispecific antibody P4-G1-M1.3 having two pairs of polypeptide chains, each pair of said two pairs comprising a heavy chain joined to a light chain by at least one heavy-light chain bond, wherein each light chain has an amino acid sequence of SEQ ID NO:204 and each heavy chain has an amino acid sequence of SEQ ID NO:226.

### Claim 196 (depends on 195)

The polyvalent bispecific antibody of claim 195, wherein at least one of said at least one bonds is a disulfide bond.

### Claim 197 (depends on 195)

The polyvalent bispecific antibody of claim 195, wherein the polyvalent bispecific antibody is more effective at inhibiting tumor growth in a human xenograft model in nu/nu mice than is a combination of an equimolar amount of each of anti-IGF-1R IgG antibody P4 and anti-ErbB3 scFv M1.3.

### Claim 198 (depends on 195)

The polyvalent bispecific antibody of claim 195 in a pharmaceutically acceptable carrier suitable for injection or infusion.

### Claim 199 (depends on 198)

A method for treating a subject having cancer, said method comprising administering to the subject a therapeutically effective amount of the polyvalent bispecific antibody of claim 198.

### Claim 200 (depends on 195)

A nucleic acid molecule encoding the heavy chain of the polyvalent bispecific antibody of claim 195.

### Claim 201

Polyvalent bispecific antibody P4-G1-C8 having two pairs of polypeptide chains, each pair of said two pairs comprising a heavy chain joined to a light chain by at least one heavy-light chain bond, wherein each light chain has an amino acid sequence of SEQ ID NO:204 and each heavy chain has an amino acid sequence of SEQ ID NO:222.

### Claim 202 (depends on 201)

The polyvalent bispecific antibody of claim 201, wherein at least one of said at least one bonds is a disulfide bond.

### Claim 203 (depends on 201)

The polyvalent bispecific antibody of claim 201, wherein the polyvalent bispecific antibody is more effective at inhibiting tumor growth in a human xenograft model in nu/nu mice than is a combination of an equimolar amount of each of anti-IGF-1R IgG antibody P4 and anti-ErbB3 scFv C8.

### Claim 204 (depends on 201)

The polyvalent bispecific antibody of claim 201 in a pharmaceutically acceptable carrier suitable for injection or infusion.

### Claim 205 (depends on 205)

A method for treating a subject having cancer, said method comprising administering to the subject a therapeutically effective amount of the polyvalent bispecific antibody of claim 205.

### Claim 206 (depends on 201)

A nucleic acid molecule encoding the heavy chain of the polyvalent bispecific antibody of claim 201.

### Claim 207

Polyvalent bispecific antibody M7-G1-M78 having two pairs of polypeptide chains, each pair of said two pairs comprising a heavy chain joined to a light chain by at least one heavy-light chain bond, wherein each light chain has an amino acid sequence of SEQ ID NO:262 and each heavy chain has an amino acid sequence of SEQ ID NO:284.

### Claim 208 (depends on 207)

The polyvalent bispecific antibody of claim 207, wherein at least one of said at least one bonds is a disulfide bond.

### Claim 209 (depends on 207)

The polyvalent bispecific antibody of claim 207, wherein the polyvalent bispecific antibody is more effective at inhibiting tumor growth in a human xenograft model in nu/nu mice than is a combination of an equimolar amount of each of anti-IGF-1R scFv M78 and anti-ErbB3 IgG M7.

### Claim 210 (depends on 207)

The polyvalent bispecific antibody of claim 207 in a pharmaceutically acceptable carrier suitable for injection or infusion.

### Claim 211 (depends on 210)

A method for treating a subject having cancer, said method comprising administering to the subject a therapeutically effective amount of the polyvalent bispecific antibody of claim 210.

### Claim 212 (depends on 207)

A nucleic acid molecule encoding the heavy chain of the polyvalent bispecific antibody of claim 207.
